BackgroundOverproduction of vascular endothelial growth factor (VEGF) in atopic dermatitis (AD) lesions has previously been observed. It is also known that platelet is an important source of VEGF and platelet factor 4 (PF-4), a potential marker of AD severity.AimTo evaluate concentrations of VEGF and its soluble receptors (sVEGF-R1 and sVEGF-R2) in the plasma of AD patients and to examine its possible correlation with disease severity and plasma concentrations of PF-4, a platelet activation marker.MethodsPlasma concentrations of VEGF and its receptors and levels of PF-4 were measured by an immunoenzymatic assay in 51 AD patients and in 35 healthy non-atopic controls. The severity of the disease was evaluated using the eczema area and severity index.ResultsAD patients showed significantly increased VEGF and PF-4 plasma concentrations as compared with the controls. Plasma concentrations of sVEGF-R1 and sVEGF-R2 did not differ between the groups. There were no remarkable correlations between plasma VEGF concentration and disease severity or between VEGF and PF-4 concentration.ConclusionsThis study shows that plasma concentration of VEGF may be increased in patients suffering from AD. It seems that plasma VEGF concentration is not a useful marker of disease severity and, apart from platelets, other cells might also release the cytokine.

The vascular endothelial growth factor (VEGF) is produced by different types of cells and has a major role in both, physiological and pathological angiogenesis. On the one hand VEGF is a strong mitotic and chemotactic factor for the endothelial cells, stimulating thus formation of new vessels, while on the other, it enhances the vascular endothelium permeability of the existing blood vessels which contributes to development and persistence of the inflammatory conditions. In the latter its activity is by 50 000 times higher than that of histamine. VEGF facilitates formation of oedema and leukocyte migration from the circulation to the site of inflammation. VEGF is also important in remodeling of the extracellular matrix. Moreover, it has an important significance in regulation of the immunological response, therefore plays a role in autoaggressive phenomena as well as immediate- and delayed-type hypersensitivity. Its role in the pathogenesis of immunological and inflammatory diseases, including allergy, asthma and different skin disorders has been indicated.

BackgroundOverexpression and enhanced release of vascular endothelial growth factor (VEGF) have been detected in various types of allergic inflammation, including asthma.AimTo further evaluate the pattern of systemic release of VEGF in atopic allergy, free circulating VEGF was measured in patients with persistent allergic rhinitis (PAR).MethodsThe concentrations of VEGF and its soluble receptors (sVEGF-R1 and VEGF-R2) in plasma were measured in patients with PAR sensitized to house dust mites and the healthy subjects.ResultsNo significant differences were found between PAR patients and healthy subjects with respect to plasma levels of VEGF and its receptors.ConclusionsIt seems that free circulating VEGF may not be elevated in PAR patients. Moreover, on the basis of the present study as well as the earlier ones, it appears likely that systemic release of VEGF varies among patients with distinct clinical manifestation of atopy; may depend on severity/activity and the extent of inflammatory response.

Dehydroepiandrosterone (DHEA) and its sulfate derivative (DHEA-S) are weak androgens produced in the adrenals and serve as primary precursors in biosynthesis of both, androgens and estrogens. These hormones are proposed to perform immunoenhancing activities and may play a crucial role in regulating cytokine production by Th1/Th2 cells; however, their role in immune-mediated diseases is controversial. The primary physiological role of DHEA-(S) and its mechanism is unclear. This review is a brief summary of relevant scientific basis as well as clinical research on the role of dehydroepian drosterone in immune haemostasis and inflammatory diseases, including asthma, atopic diseases, chronic urticaria, pointing also to the significance of dehydroepiandrosterone therapy and the related US patents (1999-2005).

Inflammatory processes and psychological states may mutually enhance each other as well as contribute to haemorheological alterations. The objective of the recent study was to determine blood rheological profile in patients with AD at different clinical stages. Blood rheology, as estimated by blood viscosity as well as deformability (elongation index-EI) and aggregation of erythrocytes (aggregation half time (AT1/2)--expressing the kinetic aspects and syllectogram amplitude (AMP)--representing total aggregation extent) were measured in 25 female AD patients, who showed clinical features of mild to severe AD and in 14 healthy subjects. There were no significant differences in blood rheological properties between patients with mild AD and the controls. A significant decrease in erythrocytes AT1/2 and AMP as well as EI were observed in severe AD patients as compared to other groups. Whole blood and plasma viscosity were similar in all groups. Both erythrocytes deformability and aggregation may be affected by pathophysiological processes associated with AD. Only AD patients with severe skin changes showed increased aggregability and decreased deformability of erythrocytes, suggesting that the phenomenon might be related to the disease activity.